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Resumo 
 
A expressão genética representa uma das vias mais complexas e importantes 
para a célula, que culminam na síntese proteica. Como tal, quaisquer erros que possam 
surgir durante estes eventos podem ser rapidamente amplificados e terem um 
impacto severo na célula. Portanto surgiram diversos mecanismos de controlo de 
qualidade para assegurar a fidelidade da expressão genética. Entre estes mecanismos 
está o decaimento do mRNA mediado por mutações nonsense (na sigla inglesa NMD – 
nonsense mediated decay) que permite rapidamente degradar transcritos que 
contenham codões de terminação de tradução prematuros (na sigla inglesa PTC – 
premature translation termination codon), reduzindo a sua abundância1. A eliminação 
destes transcritos anómalos evita a formação e acumulação de proteínas truncadas no 
C-terminal potencialmente tóxicas que, caso contrário, danificariam a célula. Assim, o 
NMD tem um papel protector contra erros genéticos, muitos dos quais originam PTCs. 
Recentemente, tem-se tornado óbvio que o NMD tem um papel mais abrangente, não 
só funcionando como mecanismo de controlo de qualidade da expressão genética, 
mas também apresenta uma importante função na regulação de transcritos 
fisiológicos2,3. De facto foi demonstrado que o NMD controla a abundância de 3 a 10% 
de todo o transcriptoma em Saccharomyces cerevisiae, Drosophila melanogaster e em 
Homo sapiens, pois estes transcritos possuem várias características que os tornam 
sensíveis à acção do NMD4. 
 Nas células humanas, este mecanismo envolve a acção dos factores UPF1 
(upframe shift), UPF2, UPF3 e dos factores SMG1 (suppressor with morphogenetic 
effects on genitalia), SMG5, SMG6 e SMG75. O NMD é activado assim que um PTC é 
identificado. Os factores UPF1, UPF2, UPF3 e SMG1 são recrutados e interagem com o 
ribossoma e com os factores de terminação de tradução eRF3 e eRF1 (eukaryotic 
release factor), formando o complexo DECID (decay inducing complex)6,7. Este 
complexo estimula a fosforilação do UPF18, o que conduz ao recrutamento dos 
factores SMG5/SMG7 ou SMG6, que activam a degradação do ácido ribonucleico 
(RNA) pela acção de exossomas5. 
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Grande parte da pesquisa sobre o mecanismo do NMD tem-se focado na forma 
como este mecanismo diferencia um PTC de um codão de terminação normal. De 
acordo com o modelo prevalente, nas células dos mamíferos a capacidade do NMD 
reconhecer um PTC depende dos complexos de junção exão-exão (na sigla inglesa EJC). 
Os EJC são complexos multiproteicos depositados a 20 a 24 nucleótidos (nt) de 
distância a montante dos locais de excisão de intrões (junções exão-exão) durante o 
splicing do mRNA precursor9. Estes complexos mantêm-se associados ao mRNA 
durante o seu transporte para o citoplasma, servindo como marcadores dos locais de 
excisão de intrões e também como plataformas de ligação dos factores do NMD, UPF2 
e UPF310–12. Durante o primeiro ciclo da tradução, se o transcrito não tiver PTC, o 
complexo ribossomal dissocia os EJCs para fora da grelha de leitura até chegar ao 
codão de terminação. No entanto, se o transcrito possuir um PTC e este se localizar a 
pelo menos 50 a 55 nt de distância a montante da última junção exão-exão, a 
elongação é terminada prematuramente e pelo menos um EJC fica associado ao 
mRNA13. Nestas condições, o EJC facilita o recrutamento e a interacção dos factores do 
NMD (UPF1, UPF2 e UPF3) com o complexo ribossomal, activando o NMD. Por outro 
lado, se o PTC se localizar depois desta fronteira localizada a 55 nts a montante da 
última junção exão-exão, o ribossoma consegue remover todos os EJCs, que não 
poderão, assim, desencadear a degradação do transcrito14. 
Contudo esta regra posicional do EJC não explica todos os transcritos 
susceptíveis de serem degradados por NMD. Existem transcritos que mesmo estando 
nas condições previstas pelo modelo (i.e.: no qual o PTC está localizado a pelo menos 
50-55 nt de distância a montante da última junção exão-exão), conseguem resistir à 
acção do NMD, como é o caso de mRNAs que contenham PTC próximos do codão de 
iniciação15. De facto, verificou-se que existem outras características do mRNA, para 
além dos EJC, que influenciam a activação do NMD. Por exemplo, trabalhos feitos pelo 
grupo laboratorial onde este projecto experimental foi desenvolvido, apontam para a 
distância física entre um PTC e a proteína citoplasmática de ligação à cauda poli-A do 
mRNA (na sigla inglesa PABPC1) como sendo um factor que afecta a activação do 
NMD16. Foi demonstrado que a PABPC1 consegue interagir com a proteína eRF3 e 
pensa-se que a PABPC1 é necessária para estimular um processo de terminação 
correcto e eficiente17,18. Para além disso, a PABPC1 consegue competir com a UPF1 
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pela ligação ao eRF3, inibindo o NMD, mesmo na presença de um EJC a jusante16,19. 
Propôs-se assim um novo modelo: se o ribossoma ao chegar ao PTC ficar fisicamente 
perto da PABPC1, ocorre terminação correcta e não há indução do NMD. No caso em 
que o ribossoma ao chegar ao PTC não possa interagir com a PABPC1, a UPF1 interage 
com o complexo eRF3/eRF1 e inicia-se o NMD11. Portanto, tendo em consideração este 
modelo e sabendo que o mRNA adquire uma conformação circular devido à interacção 
do factor eucariótico de iniciação 4G (na sigla inglesa eIF4G) com a estrutura cap na 
extremidade 5’, a PABPC1, o complexo eIF3 e o ribossoma, pode-se colocar a hipótese 
de a PABPC1 ser arrastada para a vizinhança do codão de iniciação pelo ribossoma 
durante o scanning. Nestas condições a PABPC1 encontra-se próxima o suficiente para 
competir com a UPF1, caso ocorra terminação prematura na vizinhança do codão de 
iniciação, permitindo assim explicar a resistência ao NMD dos transcritos contendo 
PTCs próximos do codão de iniciação.  
Esta tese teve como objectivo testar esta hipótese. Procedeu-se á construção 
de plasmídeos necessários para estudar a interacção do PABPC1 com o ribossoma. Os 
plasmídeos contêm a sequência da β-globina (que origina um pequeno transcrito de 
três exões cujas mutações nonsense já foram extensivamente descritas) e várias 
repetições da sequência do sítio de ligação da cápside do bacteriófago MS2. Estas 
sequências são aptámeros de RNA naturais que em conjunto com uma proteína 
recombinante contendo o N-terminal da proteína da cápside do MS2 e um anticorpo 
específico, permitem a imunoprecipitação selectiva destes transcritos e de qualquer 
proteína associada. A construção dos plasmídeos foi iniciada usando um processo de 
SOEing PCR.  
O factor de iniciação da tradução eIF3 é um complexo multiproteico que 
interage com o ribossoma e a proteína eIF4G, funcionando como um ponte entre os 
dois durante o processo de iniciação da tradução. Trabalhos feitos pelo nosso grupo 
laboratorial mostraram que as subunidades eIF3h e eIF3f podem estar envolvidas na 
interacção do ribossoma com a PABPC1 (através da eIF4G)20 e portanto podem ser 
necessárias ao deslocamento da PABPC1 para a vizinhança do codão de iniciação pelo 
ribossoma. Para testar o papel das subunidades eIF3h e eIF3f na ligação entre o 
complexo ribossomal 40S e a PABPC1 (através do eIF4G), isolou-se por 
imunoprecipitação, utilizando anticorpos anti-eIF3h ou eIF3f, os complexos 
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ribonucleoproteícos (na sigla inglesa mRNPs) de células HeLa tratadas com RNAs de 
interferência (na sigla inglesa siRNA) específicos para as subunidades eIF3h ou eIF3f, 
respectivamente. Os imunoprecipitados foram testados por Western Blot para 
detectar a presença de PABPC1, eIF4G e proteínas do ribossoma. Nas 
imunoprecipitações de mRNPs de células HeLa tratadas com siRNAs para a subunidade 
eIF3f, verificou-se uma ligeira diminuição dos níveis proteicos tanto da PABPC1 como 
do eIF4G, suportando um modelo no qual a eIF3f é responsável pela aproximação do 
complexo PABPC1/eIF4G ao ribossoma. Já a imunoprecipitação de mRNPs de células 
tratadas com siRNA para a subunidade eIF3h, não se observaram variações 
significativas na expressão da proteína eIF4G e não foi detectada a proteína PABPC1. 
Contudo a ausência de sinal da PABPC1 pode ter ocorrido devido à perca de proteína 
durante a remoção dos anticorpos para reutilização da membrana de PVDF. Além 
disso, a eficiência do silenciamento das subunidades não foi satisfatória, resultando 
numa diminuição pouco apreciável dos níveis proteicos de eIF3h ou eIF3f. Assim 
sendo, tanto o processo de imunoprecipitação e o método de silenciamento devem ser 
optimizados para que se possam tirar conclusões definitivas.  
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Abstract 
 
Nonsense-mediated mRNA decay (NMD) is a quality control pathway that 
recognizes and rapidly degrades mRNAs containing a premature termination codon 
(PTC). The prevalent model, proposes that in mammals a translation termination 
codon is generally interpreted as premature if it is localized more than 50-55 
nucleotides upstream of the last exon-exon junction. In these circumstances, during 
translation, the ribosome is not able to displace the exon junction complexes (EJCs) 
located downstream of the PTC; thus, when the ribosome reaches the PTC stalls and 
triggers NMD. However, it has been reported that mRNAs containing PTCs in close 
proximity to the translation initiation codon (AUG proximal PTCs) can substantially 
evade NMD, despite the presence of downstream EJCs. Recently, it was demonstrated 
that the cytoplasmatic poly(A)-binding protein 1 (PABPC1) is capable of inhibiting NMD 
when placed close to a PTC, even in the presence of EJCs. Taking this into account and 
that the mRNA acquires a circular conformation due to the interactions of PABPC1 
with the scaffold protein eIF4G at the 5’-Cap, eIF3 (eukaryotic initiation factor 3) and 
the 40S ribosome, we believe that the PABPC1 is relocated into the AUG vicinity during 
40S ribosome scanning. In these conditions the PABPC1 would be placed near AUG 
proximal EJCs and could be able to prevent NMD activation. To prove this hypothesis, 
we tried to construct by SOEing PCR, the necessary plasmids to demonstrate how 
PABPC1 is relocated to the AUG vicinity and that the interaction of PABPC1 and eIF4G 
with the ribosome remains stable during the first steps of elongation. Furthermore, we 
explored the eIF3h and eIF3f subunits role in bridging the 40S ribosome and the 
PABPC1/eIF4G complex. For that, HeLa cells were treated with specific short 
interfering RNAs for these eIF3 subunits and immunoprecipitation assays were 
performed with antibodies against eIF3h and f, respectively, to test the proteins, such 
as PABPC1, eIF4G and ribosomal proteins. However, the subunits silencing was not 
satisfactory and therefore, the knockdown procedure should be optimized before any 
decisive conclusions can be reached. 
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1. Introduction 
 
Eukaryotic gene expression consists of a multistep pathway that involves a 
series of highly regulated and interconnected events in which the mRNA (messenger 
ribonucleic acid) is a central player. Newly synthesized mRNA precursor transcripts 
(pre-mRNA) are subjected to removal of introns (splicing) and assembling with a set of 
RNA-binding proteins to form highly compact mRNA ribonucleoprotein particles 
(mRNPs)21,22. The content of the mRNPs evolves dynamically throughout the transcript 
lifetime, in response to diverse cellular signal networks, mediating mRNA cellular 
localization, translation and decay. Such plasticity is highly important for cellular 
homeostasis, because it provides the means to regulate gene expression, allowing the 
cells to quickly adapt to changes in their environment by altering the patterns of gene 
expression23,24.  
During eukaryotic transcription, the pre-mRNA is rapidly modified into a 
complex that contains a methylated cap structure bound to the cap-binding protein 
(CBP) heterodimer CBP80/CBP20 complex at the 5’ end and a poly(A)-tail at the 3’ end, 
bound to the nuclear poly(A)-binding protein 1 (PABPN1). These modifications not only 
protect the newly synthesized RNA transcript from premature degradation, but also 
facilitate translation initiation in the cytoplasm23,25. The pre-mRNA can also be 
subjected to splicing to remove introns and ligate the exons together. During this 
process, a complex of proteins called the exon junction complex (EJC) is deposited at 
20–24 nuclotides (nt) upstream of every exon–exon splice site within the mRNP9.  The 
EJC is a dynamic structure with a heterogeneous protein composition that evolves 
throughout the mRNA life cycle. Some of the EJC components dissociate before mRNA 
export, while others only bind in the cytoplasm. However, it is thought that a core of 
EJC components comprised of Y14, Mago–Nashi homologue (MAGOH), DEAD-box RNA 
helicase eukaryotic initiation factor 4A3 (eIF4A3) and Barentsz (BTZ; also known as 
metastatic lymph node 51: MLN51) remain associated with the mRNA escorting it to 
the cytoplasm, serving as a marker of the intron excision location, for the translational 
machinery10,11.  
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Once proper 5′ and 3′ modifications and splicing has been concluded, the 
mRNA, assembled as an mRNP, migrates through the physical barrier between the 
nucleus and cytoplasm, to reach the ribosomes and translation factors26.  At this stage, 
the 5’ cap of the majority of mRNAs are bound by the nuclear CBP80/CBP20 complex, 
whereas the 3’ poly(A) tail carries a mixture of nuclear (PABPN1) and cytoplasmic 
(PABPC1) poly(A) binding proteins. CBP80/CBP20 interacts with the eukaryotic 
translation initiation factor 4G (eIF4G), promoting the recruitment of the small 
ribosomal subunit 40S and initiate 5’3’ scanning along the 5’ untranslated region 
(UTR) for a start codon (AUG). Once the start codon is identified, the large ribosomal 
subunit 60S is engaged to form an 80S complex competent for protein synthesis, 
initiating the “pioneering round” of translation.27 In this first passage, the ribosome 
scans the mRNA, displacing any remaining nuclear-acquired mRNP proteins, such as 
EJCs, residing inside the open reading frame (ORF)14,28,29.  At some point, CBP80/CBP20 
and PABPN1 are completely replaced by the major cytoplasmic cap binding protein 
(eIF4E) and PABPC1, respectively, which directs the steady state of translation, 
supporting the bulk of cellular protein synthesis30.  
 
1.1. Eukaryotic mRNA Translation  
 
The translation process can be divided into four distinct stages, initiation, 
elongation, termination and ribosome recycling31, each requiring a particular set of 
conditions and factors.  
 
1.1.1. Translation initiation – the scanning model 
 
Translation initiation is the rate-limiting step of translation and, in eukaryotic 
cells, requires the participation of several eukaryotic initiation factors (eIF)32. The 
initiation codon recognition generally occurs through a scanning mechanism, wherein 
every triplet in the mRNA sequence is inspected for complementarity to the anticodon 
of methionyl initiator transfer RNA (Met-tRNAi). This process begins with the assembly 
of the Met-tRNAi and the GTP-bound (guanosine triphosphate) form of eIF2 into the 
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small ribosomal subunit 40S, in a process stimulated by eIF 1, 1A, 5, and the eIF3 
complex resulting in the 43S pre-initiation complex (PIC)33,34. This structure is then 
deposited near the 5’-cap with the support of the PABPC1, the eIF3 complex, and the 
eIF4F complex (which is comprised by the cap-binding protein eIF4E, the eIF4G, and 
the RNA helicase eIF4A) (fig. 1)33,35,36. 
Mammalian eIF4G is a scaffold protein that harbors binding domains for both 
PABP and eIF4E in its N-terminus and eIF4A and eIF3 in the middle and C-terminal 
region, respectively37. The interaction between eIF4G and the eIF3 complex establishes 
a protein bridge between the 43S PIC and the mRNA (fig. 1), while the ATP-dependent 
helicase activity of eIF4A unwinds the mRNA secondary structure removing secondary 
structures that impede ribosome attachment, promoting 43S PIC deposition in the 
mRNA and subsequent scanning37,38.   Simultaneous, the interaction of eIF4E and PABP 
with eIF4G brings the 3’ UTR in close proximity with 5’ UTR, giving the mRNP a circular 
conformation (fig. 1)39. This “closed-loop” structure is thought to protect both ends of 
the transcript from the mRNA degradation machinery, promotes translational control 
by regulatory elements in the 3’ UTR and stimulates ribosome initiation17,39. 
Once bound near the 5’-cap, the 43S PIC scans the mRNA for an AUG codon in 
an optimum/consensus context (Kozak context), typically the first AUG triplet with a 
purine at the -3 and a G at the +4 positions, relative to the A of the AUG codon, which 
is designated +140. Correct base-pairing between the anticodon of Met-tRNAi and the 
AUG in the peptidyl-tRNA (P) site of the 40S subunit induces arrest of the scanning PIC. 
The GTPase-activating factor eIF5 then triggers irreversible hydrolysis of the GTP 
bound to eIF2, resulting in the release of eIF2-GDP (guanosine diphosphate) and 
several other eIFs present in the PIC.  Finally, loading of the large ribosomal subunit 
60S is catalyzed by eIF5B, resulting in an 80S ribosome ready to begin the elongation 
phase(fig. 1)31,41,42. 
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Figure 1: Model of canonical eukaryotic translation initiation pathway (modified from Hinnebusch, 
2012)
42
. This pathway begins with loading of the methionine-loaded initiator tRNA bound to the eIF2-
guanosine triphosphate (eIF2.GTP.Met-tRNA) into the 40S ribosomal complex, a process that is 
stimulated by the eukaryotic initiation factors (eIF) 1, 1A, 3 and 5. The resulting 43S preinitiation 
complex is then deposited near the 5’cap of an activated mRNA, where it scans the mRNA until an 
AUG codon in a proper context is recognized. Subsequent downstream steps, including eIF2 
hydrolysis, induce eIFs release and 60S joining.      
Scanning 
AUG recognition 
Subunit joining 
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1.1.2. Translation elongation 
 
In general, the mechanism of translation elongation is well conserved between 
eukaryotes and bacteria, and most of our knowledge of the mechanistic details is 
based on prokaryotic systems43,44. The elongation stage, is characterized by the 
sequentially addition of amino acids to the carboxy-terminal end of the growing 
polypeptide chain. The string of mRNA codons (read in the 5’→3’ direction) determines 
the order in which amino acids are added to form the primary amino acid sequence of 
each protein45.  
The ribosome has three tRNA-binding sites: the A- (aminoacyl) site, which 
receives the incoming aminoacyl-tRNA, the P- (peptidyl) site, which harbors the tRNA 
with the nascent peptide chain and the E- (exit) site through which the deacylated 
tRNA leaves the ribosome46.  Following translation initiation, the 80S ribosome P-site, 
holds an Met-tRNAi base-paired with the start codon31,47, while the A-site surrounds 
the second codon of the ORF, awaiting binding of a cognate (carrying an anticodon 
with a correct match for the codon) aminoacyl tRNA48 (fig. 2). Because the codon in the 
A-site could represent any of the 64 candidates of the genetic code, a process of 
aminoacyl-tRNA sampling occurs until a cognate tRNA is selected49. Various aminoacyl-
tRNAs, guided by an accompanying eukaryotic elongation factor 1A (eEF1A) in a GTP-
dependent manner, successively enter the A-site (fig. 2). If the tRNA is not a proper 
match, the tRNA-eEF1a complex dissociates as a unit and aminoacyl-tRNA sampling 
continues. If correct codon–anticodon interactions are achieved, GTP hydrolysis is 
activated by eEF1A. This induces a major conformational change in eEF1A, releasing 
the factor and enabling the aminoacyl-tRNA to be accommodated into the A-site48,49. 
The nascent peptide chain, in P-site, is then transferred to the amino acid of the A-site 
aminoacyl-tRNA and the translocation of peptidyl-tRNA from A- to P- and of deacylated 
tRNA from P- to E- sites occurs (fig. 2). This translocation step is promoted by eEF2 in a 
GTP dependent manner45. Once translocation occurs, the ribosomal A-site becomes 
available for binding of the next aminoacyl-tRNA in a complex with eEF1A. The entire 
process is then repeated, until a stop codon is encountered. 
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1.1.3. Translation termination 
 
   Notably, stop codon recognition is the only step where a protein, the 
eukaryotic release factor 1 (eRF1), instead of a nucleic acid adaptor (tRNA) serves as 
the recognizing factor. Translation termination begins when a stop codon (UAA, UGA, 
or UAG) enters the A-site, stalling the ribosome (fig. 3). eRF1 adopts a tRNA-like 
structure and is able to recognize the termination codon, through its N-terminus, while 
the C-terminus forms a complex with the C-terminus of the GTPase eRF3. This 
interaction triggers GTP hydrolysis, inducing a conformational change positioning eRF1 
closer to the P-site. Thus, allowing eRF1 to stimulate hydrolysis of the ester bond of 
Sampling 
Codon 
recognition 
Peptide bond 
formation 
Ribosome 
translocation 
Figure 2: Model of eukaryotic translation elongation pathway (based on Keeling, 2014)
49
. In this 
pathway an aminoacyl-tRNA is carried by the eukaryotic elongation factor 1A (eEF1A) to the A-site of 
the ribosome. If the aminoacyl-tRNA possesses a cognate anticodon for the codon enclosed in the 
ribosomal aminoacyl-site (A-site), eEF1A hydrolysis is triggered allowing aminoacyl-tRNA 
accommodation within the ribosome. Subsequently, the nascent peptide chain, in the peptidyl-site (P-
site), is transferred to the aminoacyl-tRNA in the A-site and ribosome translocation occurs.  
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the peptidyl-tRNA, facilitating the release of the completed polypeptide chain (fig. 
3)5,50.  
The eRF3 also interacts with the C-terminal domain of PABPC1, through its N-
terminal domain5. The functional consequence of the PABPC1-eRF3 interaction is not 
yet fully understood. It has been shown in yeast that when the interaction between 
the eRF3 orthologue Sup35 and Pab1p is impaired, the terminating ribosome cannot 
efficiently dissociate from the mRNA51. It was also demonstrated that mammalian cells 
lacking PABPC1 exhibited increased read-through of termination codons52. Therefore it 
is believed that PABPC1 stimulates proper and efficient translation termination17,18. 
When termination is completed and both eRF3 and the polypeptide chain are 
released, the termination factor ABCE1 is able to interact with eRF1 and the stalled 
ribosome, triggering dissociation and recycling of the ribosomal subunits53. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stop codon 
recognition 
Peptide release 
Figure 3: Model of eukaryotic translation termination pathway (based on Keeling, 2014)
49
. This 
process begins once a stop codon enters the ribosomal aminoacyl-site (A-site). The ribosome stalls 
and the eukaryotic release factor (eRF1) recognize the termination codon. eRF3 hydrolysis forces 
eRF1 to be positioned closer to the peptidyl-site (P-site), stimulating peptide release. The cytoplasmic 
poly(A)-binding protein  (PABP) stimulates proper termination by a process not yet known.  
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1.2. Surveillance mechanisms 
 
Throughout the mRNA biogenesis several errors may occur. Naturally, cells 
have developed surveillance mechanisms capable of detecting and stimulating 
degradation of mRNPs that were not properly assembled and/or harboring mutations 
within the ORF1. These surveillance mechanisms operate both in the nucleus and in the 
cytoplasm, assessing the translatability of the mRNA54. So far, three different 
translation-coupled mRNA surveillance systems have been identified in eukaryotes50. 
The most recently discovered mechanism, the no-go mRNA decay (NGD) induces 
degradation of mRNAs that have secondary structures that cause a complete block of 
the translation elongation.1,55 The non-stop mRNA decay (NSD), appears to have 
evolved to stimulate degradation of mRNAs that lack a stop codon56.  In both cases, 
there is no stop codon and hence no release factors engage with the stalled 
ribosome1,50. The third and the best characterized mechanism in eukaryotes, in which 
this work will focus, is the nonsense-mediated decay (NMD). 
 
1.2.1. Nonsense-mediated decay  
 
NMD was identified almost forty years ago, when it was observed that 
nonsense codons truncating the ORF of ura3 mRNAs in Saccharomyces cerevisiae and 
the β-globin mRNAs in β0-thalassemic patients dramatically reduced the RNA half-
life57,58. This resulted in decreased abundance of the affected mRNA transcripts, rather 
than production of truncated proteins57,58. Fast degradation of mRNAs harboring 
truncated ORFs due to premature translation termination codons (PTCs) was 
subsequently reported in many other organisms, and it is believed to occur in most if 
not all eukaryotes59.  Although important aspects of the NMD mechanism can differ 
between yeast, worms, flies and humans, the core process and proteins seem to be 
conserved. Thus, NMD is described as an evolutionary conserved posttranscriptional 
quality control mechanism that identifies and rapidly induces the degradation of faulty 
transcripts containing PTCs.  Therefore, preventing the synthesis and accumulation of 
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C-terminally truncated proteins and protecting the cell from potentially deleterious 
dominant-negative or gain-of-function effects of these truncated proteins5,60 .  
 
1.2.1.1. NMD factors and mechanism 
 
NMD takes place once a PTC is identified, leading to the recruitment and 
assembly of the surveillance complex. In human cells, this complex comprises the 
factors up-frameshift 1 (UPF1), UPF2 and UPF3 (which represents the conserved core 
of the NMD machinery and is thought to assemble in all organisms) and the suppressor 
with morphogenetic effects on genitalia 1 (SMG1), SMG5, SMG6 and SMG75.  
UPF1 is an ATP-dependent RNA helicase and is the most conserved NMD factor 
and functionally the most important. It is currently unknown how UPF1 is recruited to 
the terminating ribosome, and if it is present in all termination events. However, once 
recruited, UPF1 interacts with eRF3 forming a complex with SMG1, eRF1 and eRF3, 
called the SURF complex (SMG1-UPF1-eRFs complex)8.   UPF1 also binds to UPF2 and 
UPF3 forming the decay-inducing complex (DECID), which promotes UPF1 
phosphorylation by the protein kinase SMG1 (fig. 4)6,7. As a result, UPF1 undergoes a 
conformational change that increases its affinity for RNA and induces the dissociation 
of eRF3 from UPF18.  Phosphorylated UPF1 can then recruit either the SMG7/SMG5 
heterodimer or the endonuclease SMG6.  
Interaction of SMG7/SMG5 with the phosphorylated UPF1 promotes 
deadenylation by the consecutive action of the complexes PAN2/PAN3 and 
CCR4/CAF1, followed by exonucleolytic degradation of the transcript by the exosome 
in 3’5’ direction61,62. While at the other end of the transcript, the heterodimer 
DCP1/DCP2 removes the cap structure, leaving the 5’ end accessible for rapid 
degradation by the exonuclease XRN1 in 5’3’ direction (fig. 4)24,63. Alternatively, if 
SMG6 interacts with phosphorylated UPF1, endonucleolytic cleavage is elicited in the 
vicinity of the PTC and the resulting intermediates are then rapidly degraded in the 
3’5’ direction by the exosome and in the 5’3’ direction by XRN1 (fig. 4)64.  SMG7 
and SMG6 also recruit the protein phosphatase 2a (PP2A), which promotes UPF1 
dephosphorylation and dissociation from SMG7 or SMG6, enabling the recycle of these 
proteins for a new round of NMD54. 
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In mammalian cells, multiple lines of evidence support the idea that NMD act 
exclusively on newly synthesized transcripts during the pioneer round of translation, 
before eIF4E replaces the CBP80/CBP20 complex28.  It has been shown that short 
interfering RNA (siRNA) mediated depletion of CBP80 inhibits NMD65,66, that the core  
NMD factors UPF1, UPF2, UPF3 and SMG1 co-immunoprecipitate with CBP80-
associated mRNPs28,67 and that levels of CBP80/CBP20-bound PTC-containing mRNA 
are lower than the levels of corresponding CBP80/CBP20-bound wild-type mRNA28. 
Additionally, CBP80 has also been documented to chaperone UPF1 to the terminating 
ribosome, located at the PTC, stimulating the SURF complex formation68. The first 
round of translation might even begin before the entire mRNP traverses the nuclear 
pore14, with the ribosome acting as a proofreader, triggering NMD and hence 
eliminating faulty transcripts early on, before they are committed to the eIF4E-
associated bulk translation69.  In contrast, in Saccharomyces cerevisiae NMD occurs 
mainly on eIF4E-bound mRNAs, where the CBP80/CBP20-bound transcripts are largely 
insensitive to NMD and the yeast homologue of CBP80 is dispensable for NMD70–72. In 
fact, more recently, it has been demonstrated that eIF4E-associated nonsense-
transcripts can also be efficiently degraded by NMD in mammalian cells69,73. 
Additionally, it was also observed that UPF1 co-precipitates with eIF4E in an RNA-
dependent manner69, indicating that NMD could be a regulated event that can be 
activated on substrates already engaged in translation, according to the cell needs. As 
suggested by Popp and Maquat74, the apparent mammalian NMD restriction to 
CBP80/CBP20-bound transcripts may be the result of NMD occurring more rapidly than 
the replacement of CBP80 by eIF4E74.  
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Figure 4: Model of nonsense mediated mRNA decay (NMD) mechanism and degradation stimulation via suppressor with 
morphogenetic effects on genitalia 6 (SMG6) or SMG7/SMG5 (modified from Nicholson, 2010)
5
. Once a premature translation 
termination codon (PTC) is identified, the NMD factors up-frameshift 1 (UPF1), UPF2, UPF3 and SMG1 interact with the 
eukaryotic release factor 3 (eRF3) and eRF1, forming the decay-inducing (DECID) complex. UPF2 and UPF3 recruitment and 
interaction with UPF1 is facilitated by the presence of a downstream exon junction complex. The DECID complex triggers UPF1 
phosphorylation (represented as a P) inducing eRF3 release and recruitment of either SMG7/SMG5 or SMG6. Interaction of 
SMG7/SMG5 with UPF1 promotes deadenylation and deccaping, followed by mRNA degradation by exonucleases from the 5’ and 
3’ ends. If SMG6 interacts with UPF1, the RNA is cleaved in the vicinity of the PTC and RNA is degraded in the direction of the 5’ 
and 3’ ends by exonucleases. Finally, protein phosphatase 2A (PP2A) recruitment enables UPF1, SMG7/5 and SMG6 recycling. 
DECID formation 
UPF1 
phosphorylation 
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1.2.1.2. PTC definition 
 
Trying to understand how exactly a stop codon is distinguished from a PTC has 
been the subject of intense ongoing research and discussion. Despite the core NMD 
factors appear to be conserved amongst species, several models for NMD PTC 
definition have been proposed from studies in mammalian systems compared with 
studies in Saccharomyces cerevisiae, Caenorhabditis elegans, Drosophila melanogaster 
and plants75.  
According to the prevailing model for mammalian NMD, a stop codon is 
classified as aberrant if is located more than 50-55 nucleotides upstream of the last 
exon-exon junction of a transcript. During the pioneer round of translation of a PTC 
free transcript, the 80S ribosome displaces from the ORF any EJC deposited in the 
mRNA, until it reaches a stop codon. Conversely, if the transcript possesses a PTC 
localized at more than 50-55 nucleotides upstream of the last exon-exon junction, the 
ribosome will stop before being able to remove the EJC13. Therefore, at least one EJC 
will remain bound to the mRNA and trigger recruitment of the NMD factors. The EJC 
also act as a binding platform for UPF2 and UPF3 (which is loaded onto mRNAs during 
splicing and represents a genuine EJC component)12,76, greatly enhancing the 
interaction between UPF2 and UPF3 with the SURF complex due to their close 
proximity5. In contrast, if the PTC is located at less than 50-55 nucleotides upstream of 
the last exon-exon junction of a transcript, all EJCs are removed and the NMD is not 
activated13. 
 However, recent data has challenged the generality of this EJC-dependent 
NMD model77,78. For example, the β-globin transcripts possessing a PTC near the AUG 
fail to trigger NMD, despite the existence of downstream EJCs15,79. These exceptions 
suggest that additional determinants may be involved. Indeed, there is evidence that, 
similar to what happens in yeast, the decision of whether NMD is to be triggered or 
not, relies upon competition between UPF1 and PABPC1 for binding to eRF3 on the 
terminating ribosome19,80. If PABPC1 is in close proximity to a stop codon, it interacts 
with the termination complex, stimulating proper translation termination, and 
represses NMD18. On the contrary, in the event that the spatial distance between the 
terminating ribosome and the poly(A) tail is too big, the interaction of PABPC1 with the 
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termination complex is reduced and UPF1 interacts with eRF3 triggering NMD16,52. 
Supporting this model, it has been shown that tethering of PABPC1 in the vicinity of a 
PTC abolishes NMD81,  even in the presence of a downstream EJC16 and that native 
stop codons were found to elicit NMD when 3’UTR length is increased82.  
 
1.2.1.3. Natural and aberrant targets of NMD 
 
Transcripts harboring PTCs can be generated at several stages during mRNA 
biogenesis. At the DNA level, PTC containing mRNAs can arise from germline or 
somatic alterations. Single base pair substitutions can change a sense codon to an in-
frame PTC (nonsense mutation) or more frequently frame-shifting deletions and 
insertions alter the ribosomal reading frame, causing translation ribosomes to 
encounter a PTC. Mutations at splice sites or splicing regulatory sequences may result 
in inaccurate intron removal and create an intron-derived PTC or a frameshift83,84. In 
addition, non-faulty regulated processes such as programmed DNA rearrangements 
occurring in the immunoglobulin and T-cell receptor genes during lymphocyte 
maturation generate PTCs at a high frequency, due to random deletions and the 
addition of non-template nucleotides at the recombination sites5. NMD, therefore, has 
an important role eliminating by-products of programmed DNA rearrangements and in 
the differentiation and maintenance of hematopoietic cells85.  
At the RNA level, alternative splicing constitutes a major source of PTC 
containing mRNA. A genome wide analysis predicted that ∼3,100 of 16,000 human 
genes examined should produce at least one alternative-splice product, one-third of 
which would contain PTCs86. In some cases, it constitutes a form of auto-regulation of 
the expression of the canonical protein-encoding isoforms, as the protein products of 
these genes are responsible for NMD triggering87. 
Other types of faulty mRNAs are transcripts from non-functional pseudogenes, 
endogenous retroviral and transposon RNAs or mRNA-like non-protein coding RNAs 
from intergenic regions2,4. This variety of targets infers an even broader role of the 
NMD pathway in dampening the ‘‘transcriptional noise’’ of supposedly non-functional 
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RNAs. Altogether, this advocates that cells produce a large number of faulty PTC 
mRNAs that are recognized and eliminated by NMD. 
It has become clear during recent years that many physiological mRNAs that 
encode full-length functional proteins are also NMD substrates, indicating a role for 
NMD not only in mRNA quality control, but also as a translation-dependent post-
transcriptional regulator of the steady state level of gene expression2,3. Translation 
regulation of existing mRNAs allows for a spatial and temporal fine-tuning of levels of 
the encoded proteins, allowing the maintenance of cellular homeostasis. In fact, 
several microarray studies comparing the mRNA levels of normal cells with NMD-
deficient cells in Saccharomyces cerevisiae, Drosophila melanogaster and Homo 
sapiens) revealed that NMD directly and indirectly controls the abundance of 3–10% of 
the transcriptome in the respective cells4.  
Several features of physiological mRNAs can render them NMD-sensitive. 
Introns in the 3’ UTR, transcripts containing regulatory ORFs that reside upstream of 
the primary ORF41; programmed frameshifts; or long 3’ UTRs can activate NMD88. 
Interestingly, mRNAs containing UGA triplets that direct selenocysteine incorporation 
can also elicit NMD. When selenium is abundant, UGA codes for selenocysteine. But, 
when the selenium concentration in the cell is low the UGA codon is interpreted as a 
PTC89.   
The natural NMD targets (identified so far) are involved in a variety of cellular 
processes such as stress responses, hematopoietic stem cell development, regulation 
of alternative splice forms90, genomic stability, cell-cycle, telomere length 
maintenance91 and embryonic development4, potentially allowing NMD to adapt 
protein expression in accordance with the cellular needs.  Nevertheless, these 
physiological substrates have one feature in common with their pathological 
counterparts: they possess a translation termination codon that is, by NMD standards, 
conceived as premature.  
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1.2.1.4. Biological and medical significance of NMD 
 
NMD plays an important role as a modulator of the severity of the clinical 
phenotype of many genetic diseases60. If translated, the mRNAs containing PTCs give 
rise to truncated proteins that have either completely lost their function, have 
acquired dominant-negative function, are still functional, or have gained new 
functions. As a consequence of these different possibilities, NMD can either mitigate or 
aggravate the disease outcome. NMD importance as a protective surveillance 
mechanism is highlighted by the fact that one-third of all genetic disorders, including 
many cases of cancer, are caused by nonsense mutations or frameshifts, which 
generate nonsense codons60. β-thalassemia demonstrates the protective effects of 
NMD against the production of faulty proteins. If a mutation causing premature 
translation termination is localized within exons 1 and 2 of the transcript, the defective 
β-globin mRNA is degraded by NMD and, therefore, synthesis of truncated β-globin is 
limited. The resultant excess of free α-globin and any defective β-globin, which are 
harmful to the cell, are degraded by proteolysis. But in the event, that the nonsense 
codons resides within the third (final) exon, the transcript evades NMD  allowing the 
generation of truncated protein that overwhelms the cell’s proteolytic system and 
causes toxic precipitation of insoluble globin chains92,93. In contrast, there are cases 
(such as Ullrich disease  or cystic fibrosis) in which NMD down-regulates mutant 
proteins with residual activity that can partially retain normal protein function, 
resulting in an augmentation of the defects caused by the original mutation. In these 
cases, selective inhibition of NMD may provide a novel therapeutic method 94–96. 
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1.3. The eukaryotic initiation factor 3  
 
The mammalian eIF3 is the largest (800 kDa molecular mass) and most complex 
of the eukaryotic translation initiation factors, consisting of 13 different subunits 
named from eIF3a-eIF3m97 that form three stable modules; a:b:g:i (module 1); c:d:e:l:k 
(module 2) and f:h:m (module 3)98. Comparative studies of the cDNA sequences of the 
mammalian eIF3 subunits with the entire genome of the Saccharomyces cerevisiae 
have demonstrated that the subunits eIF3a, b, c, g, i and j are conserved across 
species99–101. The eIF3a, b, c, g and i subunits are essential for translation in vivo97 and 
eIF3j despite being nonessential, is capable of enhancing interactions with other 
eIFs102, promoting binding of eIF3 to the 40S subunit103 and has an independent 
function in 40S ribosome biogenesis104. These findings suggest that these essential 
subunits provide most of the basic functions of eIF3 for translation initiation in vivo, 
and the remaining nonessencial subunits (of the mammalian eIF3) appear to modulate 
Figure 5: Representation of the position-dependent effects of nonsense mutations in the inheritance 
pattern and clinical severity of β-thalassemia (based on Holbrook, 2004)
60
. Premature translation 
termination codons (PTCs) in close proximity to the start codon do not trigger NMD but any translated 
β-chains are still small enough to be completely hydrolyzed by the red blood cell proteolytic system. If 
the PTC is located downstream of codon 23 and more than 55 nucleotides (nt) upstream of the last 
exon-exon junction, the transcript is targeted for NMD limiting protein production. In both cases the 
organism is protected from the deleterious dominant-negative effects of the truncated peptides. In 
contrast, transcripts bearing PTCs located less than 55 nt upstream of the last exon-exon junction 
produce nonfunctional β-globin proteins that are too large to be efficiently degraded, overwhelming 
the cellular proteolytic system and cause toxic precipitation of insoluble β-globin chains. 
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its activity99,105. This view is supported by the observations that module 1 can promote 
mRNA binding to 40S ribosomal subunits on its own, but to achieve a maximal 
efficiency, it requires additional support from module 2 and that downregulation of 
eIF3c and eIF3a diminishes initiation rates106. 
The mammalian subunits a, c, e, k, l, and m contain a PCI (proteasome, COP9, 
eIF3) domain, a conserved structural motif shared by the functionally unrelated 
complex proteasome lid and the COP9 (constitutive photomorphogenesis 9) 
signalosome107. Intriguingly, the subunits f and h possess an MPN (Mpr1–Pad1 N-
terminal) domain also found in related proteins in the proteasome lid and COP9107. 
These domains serve as a central structural scaffold that are involved in binding eIF3 to 
the translation initiation factors eIF1, eIF1A, and eIF2, as well as to the 40S ribosomal 
subunit108.  The interactions between eIF3 and other translation initiation factors 
control the binding of the GTP-eIF2/Met-tRNAi complex to the 40S ribosomal subunit, 
positioning the mRNA on the 40S subunit, and modulate the stringency of start codon 
selection42. Furthermore, subunits eIF3c, d, and e interact with eIF4G109, which is 
known to promote mRNA loading onto the 40S ribosome37,38. Therefore, eIF3 plays a 
central role in assembling the translation initiation complex.  
In addition, recent data demonstrate a role of the eIF3 complex in NMD. In fact, 
the mammalian eIF3e subunit, which is not required for general translation, impairs 
NMD when silenced110. Our group has also demonstrated that human eIF3h and eIF3f 
subunits are involved in the NMD-resistance of mRNAs of AUG proximal PTCs20. These 
findings further support the notion that some subunits of this multiprotein complex 
are involved in controlling different aspects of mRNA biogenesis rather than directly 
participating in translation initiation. 
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2. Aims 
 
Previous studies from our laboratory group revealed that mRNAs containing 
PTCs in close proximity to the translation initiation AUG codon (AUG proximal PTCs) 
escape NMD. This was initially surprising as these mRNAs would be expected to 
contain residual EJCs and would situate the PTC quite far, in a linear sense, from the 
poly(A) tail and PABPC115, a condition that could induce NMD. The observed NMD 
resistance was attributed as a direct effect of the translation termination event being 
located in close proximity to the AUG.  
Knowing that the mRNA acquires a circular conformation due to the interaction 
between eIF4G/PABPC1 and eIF4G/eIF4E and that the interaction between eIF4G and 
the eIF3 complex establishes a protein bridge between the mRNA and the 43S PIC (fig. 
1), we propose a model were the PABPC1 is relocated to the AUG vicinity during 43S 
scanning. Consequently, if a premature termination event takes place in the vicinity of 
the AUG, the PABPC1 might be able to compete with UPF1 for binding to eRF3, 
stimulating proper translation termination, and repressing NMD. This model 
conjectures that some initiation factors that promote scanning-dependent initiation 
may remain ribosome associated during translation of first codons111. In fact, some 
data have shown that mRNAs with AUG proximal PTCs become NMD sensitive when 
translation elongation across the short ORF is slowed down16, indicating that PABPC1 
interactions remain at the AUG vicinity during the first elongation steps, until the 
ribosome reaches the short ORF stop codon. Furthermore, there are results 
demonstrating that in HeLa cells treated with eIF3f or eIF3h subunits siRNAs, the AUG 
proximal nonsense-mutated transcripts become sensitive to NMD20. This may imply 
that these eIF3 subunits are responsible for pulling the PABPC1/eIF4G complex with 
43S subunit during ribosomal scanning and translation initiation. 
The aim of the work presented in this thesis was to clarify the mechanistic basis for 
the NMD resistance of mRNAs carrying AUG proximal PTCs and expand the current 
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models for NMD and translation. In order to accomplish that objective, the following 
goals were established: 
 
 Proving that mRNA circularization via PABPC1/eIF4G interactions, leads PABPC1 
into the AUG codon vicinity, as a consequence of 43S scanning, and that this 
interaction remains during the first elongation steps. 
 
 Identify and characterize how eIF3 interacts with eIF4G and with the 43S 
ribosomal subunit. 
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3. Materials and methods 
 
3.1. Plasmid constructs 
 
A plasmid (pE_MS2-GFP) expressing a fusion protein that contains the N-
terminal portion of MS2 coat protein was previously described16. The wild-type β-
globin gene (βWT), as well as the β-globin variants β15 (UGG→UGA), β23 
(GUU→UAG), β25 (GGU→UAG), β26 (GAG→UAG) and β39 (CAG→UAG) subcloned into 
the pTRE2pur vector (BD Biosciences) were previously described79. A β-globin 
containing three repeats of MS2 coat protein binding site in the 3’UTR 
(pGEMβNins5’UTR-MS2) was previously constructed by the laboratory group, but not 
published. 
In order to produce a β-globin gene, as well as the β-globin variants β15, β23, β25, 
β26 and β39 subcloned into a pTRE2pur vector with three repetitions of the MS2 
phage coat protein binding site in the 3’UTR (pTre_β#_3xMS2bs(3’UTR); # = WT, 15, 
23, 25, 26 or 39) the corresponding pTre_β# and pGEMβNins5’UTR-MS2 plamids 
where used as templates. All plasmids were sequenced prior to use, to verify the β-
globin WT, β-globin variants and MS2 biding site sequence integrity with primers #1 - 
#5 (table 1). pGEMβNins5’UTR-MS2 (3 µg) was subjected to an enzyme digestion with 
1 µL of BstxI (New England Biolabs), 1 µL PciI (Roche), 0.5 µL BSA (100%), 5.0 µL 
NEBuffer 3 (10X, New England Biolabs) in a total volume of 50 µL, at 37°C during 2h, to 
cut and isolate a fragment containing the 3xMS2bs (estimated size = 491 bp) to be 
used as an insert. The vector pTre_β# (# = WT, 15, 23, 25, 26 or 39) (2 µg) was also 
digested following the same procedure (fragment estimated size = 5109bp). The 
digestion product was resolved in a 1% agarose gel and the appropriate bands were 
purified with the GeneJet Gel extraction kit (NZYtech) according to the manufacturer 
protocol. The vector (pTre_β#) and the insert (3xMS2bs) were used in a ligation 
reaction (molar ratio of 1:3) with 1 µL T4 DNA ligase reaction buffer (10X, Fermentas), 
1 µg T4 DNA ligase enzyme (Fermentas) in a total volume of 10 µL, at 16°C overnight. 
The ligation product was used to transform NZY5α competent E.coli cells according to 
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the manufacturer protocol. Random colonies were selected and grown in agar medium 
overnight at 37°C, 220 rpm. The plasmid DNA was purified with the NYZtech miniprep 
extraction kit according to the manufacturer protocol and sequenced with primers #1, 
#2 and #5 (table 1). All plasmids with the correct sequence were amplified in NZY5α 
competent E.coli cells and purified with NYZtech miniprep extraction kit. 
In order to produce a β-globin gene into a pTRE2pur vector with three repetitions 
of the MS2 phage coat protein binding site at forty five nucleotides of distance 
downstream of the codon 39 (pTre_βWT_3xMS2bs(45nt_CD39)); the corresponding 
pTre_βWT and pTreβWT_3xMS2bs(3’UTR) plamids where used as templates for gene 
splicing by overlap extension (SOEing) PCR. pTreβWT (0.5 µg) was amplified with 0.5 µL 
NZYSpeedy DNA polymerase (NZYtech), 5.0 µL reaction buffer (10X, NZYtech), 2.5 µL 
MgCl2 (50 mM), 2.5 µL dNTPs (10 mM), 5.0 µL DMSO (100%), 1.0 µL BSA (100%) and 
2.5 µL of primers (10 µM)  #6-#7 (table 1) for Soeing 1 or #8-#9 (table 1) for Soeing 3, in 
a total volume of 50 µL. Thermocycler conditions were 95°C for 2 min followed by 40 
cycles of 95°C for 30 sec, 55°C for 1 min, and 70°C for 45 sec followed by a final 
extension of 70°C for 5 min. For SOEing 2, pTre_βWT_3xMS2bs(3’UTR) was amplified 
in with primers #10-#11 (table 1) following the same procedure as above, but with an 
annealing temperature of 72°C for 1 min. The SOEing 1, 2 and 3 products were 
analyzed by electrophoresis on a 2% agarose gels. The appropriate bands were purified 
with the GeneJet Gel extraction kit (NZYtech) according to the manufacturer protocol 
and quantified in a Nanodrop spectrophotometer (Thermo). 
 
3.2. Cell culture, plasmid and siRNA transfection 
 
HeLa cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), at 37°C/5% CO2. Transfections of 
cells with siRNAs were carried out when cells had a confluence of 30-40%, using 200 
pmol of siRNA oligonucleotides and 4μl of Lipofectamine 2000 Transfection Reagent 
(Invitrogen), following the manufacturer’s instructions. When indicated, a 
supplemental siRNA transfection was made 24h after the initial siRNA transfection, 
using 50 pmol of siRNA oligonucleotides and 4μl of Lipofectamine 2000. The siRNA 
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duplexes (Table 2) were designed as 19-mers with 3’-dTdT overhangs and purchased 
from Thermo. Transfections of cells with plasmids were carried out when cells had a 
confluence of 70-80%, using 200 ng of pTRE_β#_3xMS2bs(3’UTR), 800 ng pE_MS2-GFP 
and 4μl of Lipofectamine 2000 Transfection Reagent (Invitrogen), following the 
manufacturer’s instructions. 
 
Table 1: Sequences of the primers used in the current work 
Primer Sequences (5’-->3’) 
1 ACATTTGCTTCTGACACAAC 
2 GCAATGAAAATAAATGTTTTTTAT 
3 GCTCCTGGGCAACGTGCT 
4 GTGGATCCTGAGAACTTCAGGCT 
5 GTTCATGTCATAGGAAGGGG 
6 TCGGTACCCGGGGATCCTCTAGTC 
7 CCTCATGTTAACAGCATCAGGAGTGGACAG 
8 GATGCTGTTAACATGAGGATCACCCATGTT 
9 GTTGCCCATCCCAAACATGGGTGATCCTCA 
10 ATGTTTGGGATGGGCAACCCTAAGGTGAAG 
11 GAAAGAAAACATCAAGCGTCC 
12 CTGCTCATTGCAGGCCAGAT 
13 GAGCCTGGGCCATGAAGAG 
14 CACCCAGTCATTTTGGCCTC 
15 CGACAGTTCCCAACAGGGTC 
16 ACCAAGAGAGTTGTCCGCAGTG 
17 TCATGGCATTACGGATGGTCC 
18 CCATGAGAAGTATGACAACAGCC 
19 GGGTGCTAAGCAGTTGGTG 
 
Table 2: Sequences of the siRNAs used in the current work 
siRNA Sequences (5’-->3’) 
eIF3f1 AUACGCGUACUACGACACU 
eIF3f2 GUGAAGGAGAAAUGGGUUU 
eIF3h1 GAUCGGCUUGAAAUUACCA 
eIF3h2 ACUGCCCAAGGAUCUCUCU 
eIF3c UGACCUAGAGGACUAUCUU 
GFP GGCUACGUCCAGGAGCGCAC 
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3.3. Immunoprecipitation assay 
 
HeLa cells cultured in 35-mm dishes and treated with siRNAs were collected 
48h after transfection. Cells were lysed in 150 μl of NP40 buffer [50 mM Tris-HCl 
pH=7.5; 10 mM MgCl2; 100 mM NaCl; 10% (v/v) Glicerol; 1% (v/v) Nonidet P-40 and 1% 
(v/v) protease inhibitor mixture (Sigma). Additionally, 0.4 µL of RNase inhibitor (40 
U/µL; NZYtech) were added to the samples not intended to be treated with RNAse A. 
Total lysates were cleared by centrifugation at 5000 rpm for 10 min at 4 °C and 20 μl 
were collected for RNA extraction or protein analysis with 4 μl 5x SDS loading buffer 
(Pre-IP). The remaining lysates were incubated overnight at 4°C with rabbit polyclonal 
anti-eIF3F (Abcam) or rabbit monoclonal anti-eIF3H (Cell Signaling) at a 1:50 dilution in 
a vertical rotator (Grant bio). Thirty μl of protein G-agarose beads (Roche) and 100 
mg/mL of RNAse A (Quiagen) were then added to the corresponding samples. After an 
incubation of 1 hour at 4°C, the samples were washed three times with excess NP40 
buffer and ressuspended in 25 μl of 2x SDS sample buffer (IP). 
 
3.4. Cycloheximide treatment 
 
HeLa cells were grown in Dulbecco’s modified Eagle’s medium supplemented 
with 10% fetal bovine serum, in 35-mm plates, at 37°C/5% CO2. Once they achieved 90-
100% confluence, the medium was replaced with a fresh one containing cycloheximide 
(CHX, Sigma). The cells were in incubated at 37°C/5% CO2 for 2h and then lysated.   
 
3.5. SDS-PAGE and Western blotting 
 
Protein lysates were resolved, according to standard protocols, in 12% SDS-
PAGE electrophoresis and transferred to PVDF membranes (Bio-Rad). The membranes 
were probed using mouse polyclonal anti-α-tubulin (Sigma) at 1:500 dilution (as a 
loading control), rabbit polyclonal anti-PABPC1 (Cell Signaling) at 1:500 dilution, rabbit 
monoclonal anti-eIF3H (Cell Signaling), rabbit polyclonal anti-CBP80 (generous gift 
from E. Izaurralde), rabbit polyclonal anti-eIF4G (Cell Signaling), mouse monoclonal 
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anti-eIF4E (Santa Cruz), mouse monoclonal anti-RPS6 (Cell Signaling) at 1:250 dilution, 
rabbit anti-c-myc (Santa Cruz) at 1:500 dilution and rabbit polyclonal anti-
enterobacteriophage MS2 coat protein antibody (Merck Millipore) at 1:250 dilution. 
Detection was carried out using secondary peroxidase-conjugated anti-mouse IgG (Bio-
Rad), anti-rabbit IgG (Bio-Rad) antibodies followed by chemiluminescence. 
 
3.6. RNA isolation 
 
Total RNA from transfected cells was prepared using the Nucleospin RNA 
extraction (Marcherey-Nagel) following the manufacturer’s instructions. 
 
3.7. Reverse transcription  
 
cDNA was prepared by incubating 1 µg of purified total mRNA with 1 µL of 
dNTPs (10 µM) and 1 µL of random primers (0.25 µg/ µL), in a total volume of 15 µL, 
during 5 min at 65°C. Then, the mixture was incubated in ice and 2 µL of reaction 
buffer (10X; NZYtech), 0.1 µL of ribonuclease inhibitor (40 U/µL; NZYtech) and 0.5 µL of 
reverse transcriptase (200 U/µL; NZYtech) was added, to a final volume of 20 µL. 
Finally, the mixture was incubated in a thermocycler at 25°C for 10 min, 50°C for 50 
min and 85°C for 5 min. cDNA was stored at 4°C. 
 
3.8. Semiquantitative PCR  
 
Three dilutions (1:1; 1:2 and 1:4) were prepared using the RT product. 5 µL of 
each of the diluted samples were amplified with 0.2 µL of Taq DNA polymerase (5 
U/µL; Ambion), 2.5 µL of 10X PCR buffer (with 15 mM MgCl2; Ambion), 0.5 µL of dNTPs 
(10 mM) and 1 µL of each corresponding forward and reverse primer (table 1; #12-13 
for eIF3H; #14-15 for eIF3F and #16-17 for eIF3C), in a total volume of 25 µL.  The same 
procedure was carried out in parallel, but using GADPH specific primers (table 1, #18-
19) as an internal standard. Thermocycler conditions were 95°C for 5 min followed by 
27 cycles of 94°C for 45 sec, 55°C for 45 sec, and 72°C for 45 sec, followed by a final 
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extension of 72°C for 5 min. Ten-microliter aliquots from each sample were analyzed 
by electrophoresis on 2% agarose gels. 
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4. Results 
 
4.1. ptre_βWT_3xMS2bs(45nt_CD39) construction by SOEing PCR 
 
 To test the hypothesis that mRNA circularization via PABPC1/eIF4G 
interactions, leads PABPC1 into the AUG codon vicinity, as a consequence of 43S 
scanning, and that this interaction remains during the first elongation steps, we tried 
to construct by SOEing PCR a plasmid containing the β-globin sequence and three 
repetitions of MS2 coat protein binding site (3xMS2bs) 45 nt downstream of codon 39. 
This construct would allow the capture of β-globin mRNPs to study PABPC1 
interactions with the ribosome. Using ptre_βWT as a template the 5’UTR of βWT 
(containing a ClaI restriction site) and codons 1-54 were amplified with primers #6-#7 
(fig. 6 and 7; lane S1). Codon 55 until the beginning of exon 2 (containing a BbrPI 
restriction site) was amplified with primers #8-#9 (fig. 6 and 7; lane S3). Both S1 
(expected fragment size = 409 bp) and S3 (expected fragment size = 191 bp) fragments 
were successfully amplified at annealing temperature of 55°C. The three repetitions of 
MS2 binding site were amplified with primers #10-#11 using the plasmid 
ptre_βWT_3xMS2bs(3’UTR) as a template (fig. 6 and 7; lane S2). The 3xMS2bs 
(expected fragment size = 93 bp) was only successfully amplified at an annealing 
temperature of 72°C. However, due to the repeated sequence of the MS2 binding site, 
1x MS2bs was also amplified (expected fragment size = 43 bp) alongside other 
unspecified products, resulting in a lower quantity of the desired fragment. This in 
combination with the 3xMS2bs small size made the purification step very inefficient. 
Therefore the 3xMS2bs fragment was not obtained with the quantity and quality 
necessary to continue the plasmid construction. 
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 Figure 7: ptre_βWT_3xMS2bs(45nt_CD39) construction by SOEing PCR. Agarose gel photos of the 
amplification products of the ptre_βWT plasmid with primers #6-#7 (lane S1) or with primers #8-#9 
(lane S3) and the ptre_βWT_3xMS2bs(3’UTR) plasmid with primers #10-#11 (lane S2). 
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150 
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Figure 6: Schematic diagram of SOEing PCR. Using ptre_βWT as a template, the 5’ untranslated 
region (UTR) and codons 1-54 of the normal human β-globin gene (βWT) were amplified with primers 
#6-#7 (Table 1), while the sequence from codon 55 (localized 45 nucleotides downstream of codon 
39) until the beginning of exon 2 were amplified with primers #8-#9 (Table 1). The primers used for S1 
and S3 contain overlapping sequences with the MS2 binding site (MS2bs) sequence. The three 
repetitions of MS2bs were amplified with primers #10-#11 (Table 1) using the plasmid 
ptre_βWT_3xMS2bs(3’UTR) as a template. The primers used for S2 amplification contained 
overlapping sequences for the ptre_βWT, upstream and downstream of codon 55. Extension of these 
overlaps, by DNA polymerase, creates the full-length mutant molecule of S1, S2 and S3 fragments. 
S1 S2 S3 
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4.2. Anti-enterobacteriophage MS2 coat protein antibody test 
 
 The coat protein binding site of the MS2 bacteriophage is a naturally occurring 
RNA aptamer112 that in conjunction with the MS2 coat protein (MS2cp) and a specific 
antibody for the MS2cp can selectively immuneprecipitate the corresponding mRNA 
transcripts and any protein attached, thus providing a robust method to study the 
RNA–protein interactome113,114. Before proceeding with MS2 immunoprecipitations 
the anti-enterobacteriophage MS2 coat protein antibody specificity and conditions 
were tested (fig. 8). HeLa cells were transfected with pTre_BWT_3xMS2(3’UTR) 
plasmid and the pE_MS2-GFP plasmid, which codifies a fusion protein containing 
MS2cp. Lysates were generated 24 hours after transfection and probed with the anti-
MS2cp antibody or anti-α-tubulin as a loading control. According to the manufacturer 
instructions, the MS2cp signal should appear around 13 kDa, however since the 
protein expressed is a fusion protein the observed band size corresponding to MS2-
GFP was around 40 kDa (fig. 8). The bands at 35 kDa and 25 kDa correspond to 
uncharacterized interactions. No band was detected in non-transfected HeLa cells (fig. 
8; lane 6), confirming the antibody specificity. 
 
 
 
 
 
 
 
 
 
 
Figure 8: Test of anti-enterobacteriophage MS2 coat protein antibody. Western blot analysis of HeLa 
cells extracts transfected with a plasmid containing the β-globin sequence with three repetitions of 
MS2 coat protein binding site at the 3’UTR and a plasmid that codifies for a MS2 coat protein fused 
with the green fluorescent protein (GFP). Lysates were generated 24h after transfection and analyzed 
with a specific antibody for MS2 coat protein and with anti-α-tubulin (α-tub) as a loading control. 
α - tub 
MS2-GFP 40 kDa 
35 kDa 
25 kDa 
   1        2       3      4        5       6 Lane 
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4.3. Cycloheximide concentration test 
 
Besides using the ptre_βWT_3xMS2bs(45nt_CD39) to capture and study the 
mRNPs, HeLa cells would also be treated (or untreated) with cycloheximide (CHX). This 
is a common laboratory reagent that inhibits protein synthesis by binding the ribosome 
in the E-site and blocking eEF2-mediated translocation. Due to its size, CHX has a 
bigger affinity for the E-site when it is empty, i.e. when the ribosome is at the AUG. It 
was shown that CHX can cause about half of the ribosomal population to stop at the 
very first codon115. Taking advantage of this, CHX treatment would facilitate the 
capture of the mRNPs near the AUG, allowing the analysis of the interaction of PABPC1 
and eIF4G with the ribosome (through eIF3) near the start codon. The necessary 
concentration of CHX to restrict protein synthesis was assessed in HeLa cells treated 
with different concentration of CHX for 2 hours (fig. 9). Lysates were generated 
afterwards and CHX effect on translation was evaluated by controlling C-myc protein 
levels by Western blot. The c-Myc protein is normally degraded very rapidly with a 
half-life of 20 to 30 min116. Therefore if translation elongation was blocked for 2h, it 
should be expected to see a decrease of the C-my protein levels. In fact, the Western 
blot shows a decrease of C-myc protein level of about 40% in the samples treated with 
150 µg/mL of CHX (fig. 9; lane 6), indicating that at this concentration, the CHX should 
be able to interfere with translation in HeLa cells. 
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Figure 9: Test of cycloheximide (CHX) concentration necessary to inhibit translation. Western blot 
analysis of HeLa cells extracts treated with different concentrations of CHX.  HeLa cells were 
incubated with CHX for 2h. Lysates were analyzed with a specific antibody for c-myc and with anti-α-
tubulin (α-tub) antibody as a loading control. An estimative of the ratio (in %) of c-myc to α-tub is also 
represented. 
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4.4. eIF3h, eIF3f and eIF3c subunits knockdown 
 
Before proceeding to the immunoprecipitation (IP) experiments to assess the 
eIF3h, eIF3f and eIF3c role in the interaction between PABPC1 and eIF4G with the 
ribosome, the knockdown efficiency of these subunits was tested at the protein level 
(fig. 10). HeLa cells were treated with 200 pmol of specific siRNAs for each subunit 
(table 2 – siRNA eIF3f1, eIF3h1 or eIF3c respectively) or with siRNA GFP as a 
transfection control. Lysates were generated 48 hours later and analyzed by Western 
blot with specific antibodies or with α-tubulin as a loading control. Silencing was 
achieved for both eiF3h (fig. 10A; lane 1) and eiF3c (fig. 10C; lane 1) when compared 
with the lysates treated with siRNA GFP (fig. 10A and 10C; lane 2), with an estimated 
knockdown efficiency of 50% and 80%, respectively. For eIF3f silence however, no 
eiF3f signal was detected (fig. 10B; lane 1 and 2). This may indicate that the quantity or 
the conditions utilized for the detection of eIF3 were not adequate.  
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Figure 10: Test of the conditions for the eukaryotic initiation factor 3h (A), eIF3f (B) and eIF3c (C) 
subunits knockdown. Western blot analysis of HeLa cells extracts transfected with siRNA eIF3h1 (A; 
lane 1), siRNA eIF3f1 (B; lane 1), siRNA eIF3c (C; lane 1) or with a control green fluorescent protein 
(GFP) siRNA (lane 2A, 2B and 2C). Cell lysates were obtained 48h post transfection and siRNA 
silencing efficiency was analyzed with specific antibodies and with anti-α-tubulin (α-tub) as a loading 
control. An estimative of the percentage of achieved knockdown (% KD) is represented below each 
lane. 
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4.5. Immunoprecipitation of mRNP complexes from HeLa cells treated with 
siRNAs specific for the eIF3f subunit 
 
To test whether the eIF3f subunit mediates the interaction between PABPC1 
and eIF4G with the 40S ribosome during initiation scanning, immunoprecipitation (IP) 
of mRNPs from HeLa cells depleted of eIF3f subunits were carried out, in the 
conditions previously tested (fig. 10). HeLa cells were transfected with 200 pmol of 
siRNA GFP or with siRNA eIF3f1 (Table 2). The lysates were obtained 48 hours later and 
the mRNP complexes were isolated by immunoprecipitation, using an antibody specific 
for eIF3h. Immunoprecipitation was performed in the presence or absence of RNase A, 
to test for protein interactions dependent or independent of mRNA. A 20 µL aliquot 
from each sample, representing the total lysate, was taken before 
immunoprecipitation (Pre-IP). The presence of PABPC1, RPS6 and other initiation 
factors was assessed by Western blot (fig. 11). α-Tubulin was used as a loading control 
and has expected, it was not detected in IP samples (fig. 11; lane 3-5), showing that the 
washing procedure, to remove any nonspecifically bonded proteins, was effective. 
Efficiency eIF3f knockdown was evaluated with an anti-eIF3f antibody. 
Comparing the eIF3f band of the Pre-IP samples (fig. 11; lane 1 and 2) there is no 
discernible differences, in terms of eIF3f protein level, between samples treated with 
control siRNA (fig. 11; lane 1) or with siRNA eIF3f1 (fig. 11; lane 2). Both signals have 
the same intensity and also there is no difference in the loading control. This indicates 
that eIF3f silencing did not have any effect, at least at the protein level. In the IP 
samples no eIF3f protein was detected (fig. 11; lane 3-5). Instead a band (50-55 kDa) 
corresponding to the heavy chain of the immunoglobulin G (IgG) was observed. This 
signal is detected because the anti-eIF3h antibody used during IP is also eluted from 
the beads and size-fractionated by SDS-PAGE. Since the IP antibody and the Western 
blot primary antibody are from the same species, the secondary antibody will also 
recognize it. This signal was always detected when a primary antibody of the same 
species was used in Western Blot and exclusively in the IP samples. 
Despite the eIF3f subunit silencing apparently not working as expected, some 
interesting variations can be pointed out. eIF4G, PABPC1 and CBP80 co-
immunoprecipitate with eIF3h and were detected in the IP samples even when treated 
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with RNase A (fig. 11; lane 4). These results imply that the interaction of these proteins 
with eIF3h is independent of RNA. Both eIF4G and PABPC1 signals in IP samples 
treated with control siRNA (fig. 11; lane 3) are stronger than the signals of siRNA eiF3f 
(fig. 11; lane 4 and 5) treated samples. This suggests that eIF3f silencing interfered with 
PABPC1 and eIF4G interaction with the eIF3h subunit. On the other hand, samples 
treated with siRNA eIF3f (fig. 11; lanes 4 and 5) also exhibit a weaker eIF3h protein 
signal when compared with the control (fig. 11; lane 3). Therefore the decreased 
interaction of eIF4G and PABPC1 with eIF3h observed in samples treated with siRNA 
eIF3f, may be due to eIF3f silencing destabilized eIF3h, and not because eIF3f mediates 
the interaction between eIF4G and PABPC1 with eIF3h and the ribosome. The mRNA 
levels of eIF3h would have to be assessed to see if the siRNA eIF3f1 is not affecting 
eIF3h expression. Additionally, this differences seen could also be a case of lane 3 (fig. 
11) having more sample quantity than lane 4 and 5 (fig. 11). Since α-tubulin was not 
detected, has expected, in the IP samples, it is difficult to assess if the protein loading 
was equal across lanes 3-5 (fig. 11).   
RPS6, a component of the 40S ribosomal unit, was not detected in IP samples, 
in either control (fig. 11; lane 3) or siRNA eIF3f (fig. 11; lane 4 and 5) treated cells. In 
Pre-IP samples, however, the RPS6 signal of the control sample (fig. 11; lane 1) is more 
intense than the siRNA eIF3f treated sample (fig. 11; lane 2), suggesting that the 
silencing treatment interfered with RPS6 expression. RPS6 mRNA levels would have to 
be analyzed to confirm this difference. The protein eIF4E was not detected in IP 
samples (fig. 11; lane 3-5) and is barely seen in Pre-IP samples (fig. 11; lane 1 and 2). 
This was unexpected since eIF4E supports the bulk of translation; therefore, it should 
be more abundant than CBP80. Nonetheless, the absence of eIF4E and RPS6 in the IP 
samples suggests that these proteins do not co-immunoprecipitate with eIF3h. 
Conversely, this could be an experimental artifact. In fact, the PVDF membrane was 
probed and reprobed several times and part of the protein may have been gradually 
washed away during removal of primary and secondary antibodies, resulting in a weak 
protein signal in Pre-IP samples and no signal in the IP samples (which had less protein 
quantity than the Pre-IP samples to begin with). A newly prepared membrane would 
have to be probed to assess if eIF4E and RPS6 does or does not co-immunoprecipitate 
with eIF3h. 
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Figure 11: Immunoprecipitation of mRNP complexes from HeLa cells treated with siRNAs specific 
for the eukaryotic initiation factor 3f (eIF3f). Western blot analysis of HeLa cells extracts transfected 
with human eIF3f siRNA (lane 2, 4 and 5) or with a control green fluorescent protein (GFP) siRNA 
(lane 1 and 3). HeLa cells lysates were obtained 48 hours after transfection with GFP siRNA or siRNA 
targeting the eIF3f subunit. Immunoprecipitation (IP) was accomplished with an antibody specific to 
eIF3h (lanes 3-5). Immunoprecipitation was carried out in the presence (lane 4) or absence (lane 5) of 
RNAse A. Lanes 1 and 2 correspond to aliquots of cell lysates prior to IP (Pre-IP). α-tubulin (α-tub) was 
used as a loading control. 
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4.6. Immunoprecipitation of mRNP complexes from HeLa cells treated with 
siRNAs specific for the eIF3h subunit 
 
The eIF3h subunit role in the interaction of PABPC1 and eIF4G with the 40S 
ribosome during translation initiation was also tested in cells depleted of eIF3h. HeLa 
cells were either transfected with 200 pmol of siRNA GFP or with siRNA eIF3h1 (Table 
2). The lysates were obtained 48 hours later and the mRNP complexes were isolated by 
immunoprecipitation, using an antibody specific for eIF3f or with protein G-agarose 
beads alone (mock) to control for nonspecific immunoprecipitation. IP was performed 
in the presence or absence of RNase A. An aliquot from each sample, representing the 
total lysate, was taken before immunoprecipitation (Pre-IP) for protein and RNA 
analysis. The presence of PABPC1 and initiation factors was assessed by Western blot 
and α-tubulin was used as a loading control (fig. 12). eIF3h silencing efficiency was 
evaluated at the protein level using an anti-eIF3h antibody (fig. 12) and at the RNA 
level by a semiquantitative PCR (fig. 13).  
Western blot analysis of eIF3h knockdown shows no distinct differences 
between GFP siRNA treated samples (fig. 12; lane 1) and siRNA eIF3h treated samples 
(fig. 12; lane 2). Contrariwise, the eIF3h RNA endogenous levels in cells treated with 
siRNA eiF3h (fig. 13; lane 9-11) are clearly lower than those treated with control siRNA 
(fig. 13; lane 3-5). In fact the lane 9 band (dilution 1:1; fig. 13) intensity is weaker than 
the band (dilution 1:2) in lane 4, indicating a silencing efficiency of at least 50% at the 
RNA level. 
Both eIF4G and PABPC1 were probed with specific antibodies. eIF4G was again 
detected in an RNA independent manner in IP samples (fig. 12; lane 4-7). PABPC1, 
however, was not detected in IP samples, suggesting that it does not co-precipitate 
with eIF3f. This is surprising, because PABPC1 forms a specific complex with eIF4G, which 
directly interacts with the eIF3 protein that co-immunoprecipitats with eIF3f. Additionally, 
PABPC1 is also bound to the poly-A tail, so it was expected that at least the PABPC1 signal 
could be observed in control IP samples not treated with RNAse A (fig. 12; lane 4).  This can 
be, once again, a case of the protein content loss due membrane washing and 
reprobing. A newly prepared membrane would have to be probed to confirm these 
findings. 
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Figure 12: Immunoprecipitation of mRNP complexes from HeLa cells treated with siRNAs specific for 
the eukaryotic initiation factor 3h (eIF3h). Western blot analysis of HeLa cells extracts transfected 
with a control green fluorescent protein (GFP) siRNA target (lane 1, 3, 4 and 5) or with human eIF3h 
siRNA (lane 2, 6 and 7). Cell lysates were obtained 48 hours after transfection with GFP siRNA or 
siRNA targeting eIF3h and immunoprecipitated with an antibody to eIF3f (lanes 4-7) or with protein G-
agarose beads only (lane 3). Immunoprecipitation was carried out in the presence (lane 5 and 7) or 
absence (lane 4 and 6) of RNAse A. The lysates were analyzed for the presence of PABPC1 and 
initiation factors by immunoblotting. Lanes 1 and 2 correspond to aliquots of cell lysates prior to IP 
(pre-IP). α-tubulin (α-tub) was used as a loading control.  
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Figure 13: Quantification by reverse transcription coupled semiquantitative (SQ) PCR of the 
eukaryotic initiation factor 3h (eIF3h) knockdown efficiency. Representative SQ-PCR analyses of 
cDNA obtained from RNAs extracted from green fluorescent protein (GFP; lane 3-8) or eIF3h (lane 9-
14) siRNA-treated HeLa cells. SQ-PCR was carried out with eIF3h mRNA specific primers to monitor 
endogenous eIF3h expression or with glyceraldehyde-3-phosphate dehydrogenase (GADPH) mRNA 
specific primers as an internal standard. Lane 1 and 2 represent blank samples with eIF3h primers or 
GAPDH specific primers. Sample dilution is also represented. 
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4.7. eIF3h, eIF3f and eIF3c subunits knockdown with different siRNAs  
 
 Since the previous knockdown procedure was not satisfactory, at least at the 
protein level, in both immunoprecipitation experiments, eIF3h, eIF3f silencing was 
repeated using a new set of siRNAs: siRNA eiF3h2 and siRNA eIF3f2, respectively (table 
2). Cells were transfected with 200 pmol of the respective siRNAs and 24 hours later, 
cells were transfected again with 50 pmol of siRNAs. Lysates were generated 48 hours 
after the initial transfection and analyzed by Western blot with specific antibodies or 
with α-tubulin as a loading control (fig. 14). Silencing was achieved for both eIF3f (fig. 
14; lane 3) and eIF3c (fig. 14; lane 5). However the new set of siRNAs for eiF3h was not 
able to interfere with eiF3h expression, even with the additional transfection step (fig. 
14; lane 1).  
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Figure 14: Analysis of the eukaryotic initiation factor 3h (A), eIF3f (B) and eIF3c (C) subunits 
knockdown efficiency. Western blot analysis of HeLa cells extracts transfected with human eIF3h 
siRNA (A; lane 1), eIF3f siRNA (B; lane 1), eIF3c (C; lane 1) or with a control green fluorescent protein 
(GFP) siRNA target (A, B, C; lane 2). Cells were transfected with 200 pmol siRNAs followed by a new 
transfection of 50 pmol of siRNAs 24h later. After 24h, siRNA silencing efficiency was analyzed with 
specific antibodies and with anti-α-tubulin (α-tub) as a loading control. An estimative of the 
percentage of achieved knockdown (% KD) is represented below each lane. 
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5. Discussion 
 
5.1. Proving that PABPC1/eIF4G remains associated with the ribosome, 
through eIF3 interaction, during the early stages of elongation 
 
 Using β-globin mRNA (a small transcript of three exons, whose NMD profile has 
been extensively characterized) as the primary model, it was shown that transcripts 
containing PTCs in the latter half of the first exon, up to the third exon, are targeted for 
NMD, which can be attributed to the existence of downstream EJCs. However β-globin 
transcripts bearing PTCs localized up to 23 codons (AUG proximal PTCs) into the open 
reading frame effectively evade NMD (fig. 5). This was unexpected since there are EJCs 
still residing downstream. It was demonstrated that this resistance reflects a close 
proximity of the PTC to the translation initiation codon and are not caused by defects 
in transcript splicing, impaired translation, or reinitiation of translation 3’ to the 
PTC15,79,117,118.  
Recently, it has been verified that PABPC1 can compete with UPF1 for eRF3 
binding, when a ribosome is poised in a stop codon, diminishing NMD response16,19 . 
Additionally, it is also known that mRNAs form a closed-loop structure during 
translation, as a consequence of eIF4G interaction with PABPC1, eIF4E, eIF3 and the 
ribosome. With this findings, it was proposed that PABPC1 possesses a major role 
protecting mRNAs harboring AUG proximal PTCs from the NMD surveillance 
pathway16,24.   
Assuming the retention of ribosome association with eIF3 and PABPC1 (through 
eIF4G) during scanning and the early stages of elongation, we propose that PABPC1 is 
repositioned in close proximity to an early PTC, during ribosome scanning, inhibiting 
NMD and enhancing the efficiency of the translation termination. This model is 
supported by the fact that tethering of PABPC1 in the vicinity of a PTC inhibited NMD16 
and the observations that eIF3 can remain bound to the translating ribosome during 
the initial phase of elongation97,119.   
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To investigate if PABPC1 is in fact translocated during initiation scanning and 
that remains in the vicinity of the AUG during the first steps of elongation, the 
pTre_βWT_3xMS2bs(45nt_CD39)  was designed. The introduction of multiple MS2bs 
into the β-globin sequence would facilitate the isolation of β-globin mRNPs, by 
immunoprecipitation assays, allowing the analysis of PABPC1 interactions with the 
ribosome and other proteins of the mRNP. The ptre_βWT_3xMS2bs(45nt_CD39) 
plasmid assembly was initiated using a SOEing PCR approach (fig. 6), a method of 
recombining sequences without depending on restriction sites or ligase. This process 
involves using primers to introduce segments of identical sequence (called the overlap 
region) in the amplified fragments. Then, during overlap PCR, the overlapping 
segments anneal and act as primers of one another. Extension of this overlap by DNA 
polymerase creates the full-length mutant molecule of both fragments. The 3xMS2bs 
fragment (fig. 7; lane S2), however, proved to be rather difficult to amplify. Owing to 
the presence of several repetitions of the MS2bs in the pTre_βWT_3xMS2bs(3’UTR), 
the primer could anneal with any of them, resulting in a PCR product containing 
fragments with 1 or several repetitions of MS2bs. Several PCR conditions were tested, 
but none resulted in a satisfactory amount of the fragment of interest (containing 
3xMS2bs). Moreover, the fragment is relatively small (93 bp) making purification 
problematic.  
An alternative process of construction could be using site directed mutagenesis 
to flank 3xMS2bs with a pair of restriction sites, such as SalI and XhoI, at 5’ and 3’ 
respectively. These enzymes recognize very similar sequences and produce compatible 
cohesive ends. The resulting fragment, containing the 3xMS2bs could then be 
subcloned into the vector containing the β-globin sequence with a XhoI restriction site 
at 45 nt downstream of the codon 39. The advantage of this method is that the ligation 
of the insert into the XhoI site of the β-globin will produce an XhoI restriction site at 5’, 
that can be cleaved to insert more 3xMS2bs if needed114. The addition of multiple 
MS2bs admits more coat protein, which could improve pulldown efficiency during 
immunoprecipitation assays. 
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5.2. Identification and characterization of eIF3 interactions with eIF4G and 
the 40S ribosomal subunit 
 
Human eIF3 is an 804 kDa protein complex containing 13 nonidentical subunits, 
named from 3a to 3m. Six of these subunits (eIF3a, b, c, g, i and j) are conserved in 
sequence across species, and are thought to provide most of the basic functions of 
eIF3120.  eIF3f and h are part of the nonconserved core and with eIF3m constitute a 
stable module that is located on the periphery of the complex98. Both eIF3f and eIF3h 
contain a MPN domain that is usually found in components of large protein complexes 
and have been implicated in protein-protein interactions supporting a possible 
interaction of these proteins with other initiation factor complexes121.   
Our group has shown that AUG proximal nonsense-mutated transcripts are 
NMD resistant but become sensitive to NMD when HeLa cells are treated with siRNAs 
specific for the eIF3h, eIF3f20 and eIF3c (unpublished) subunits, supporting the notion 
that eIF3 subunits might be involved in the delivery of eIF4G-associated PABPC1 to the 
vicinity of the AUG proximal PTC.  
To study the role of the eIF3h and eIF3f subunits, mRNPs from HeLa cells 
treated with specific siRNAs for these subunits were isolated and examined. Overall 
the IP procedure of mRNPs from HeLa cells treated with eIF3f specific siRNAs (fig. 11) 
was successfully accomplished. The proteins expected to be bound to the mRNP were 
detected, although some proteins (PABPC1, eIF4G and CBP80) were only visible (in IP 
samples) with higher (5-10 min) exposure times to the X-ray film, resulting in higher 
backgrounds. In comparison, IP pulldown efficiency in HeLa cells treated with eIF3h 
siRNAs was even lower. As a result, the proteins detected in IP samples were barely 
visible even with a 10 min exposure to the X-ray film. Nonetheless, in both IP 
experiments, a bead and antibody quantity optimization can be performed to improve 
precipitation efficiency. Furthermore, during Western blot analysis of the IP samples it 
was visible the IgG heavy chain signal, around 50-55 kDa. This made eIF3f detection 
harder. The IgG signal can be omitted simple using a probing antibody raised in a 
different species than the one used for IP, or using protein G conjugated with 
horseradish peroxidase (HRP), which binds only to the native IgG structure and not to 
its reduced forms, instead of conventional HRP-secondary antibodies. Alternatively, 
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the antibody used for IP can be covalently linked to the agarose beads. Therefore 
during elution the antibody remains with the beads. This also has the advantage of 
increasing IP specificity, giving cleaner backgrounds. However, less represented 
proteins may not be precipitated.  
Surprisingly, in both IP experiments, eIF3h and eIF3f protein knockdown 
efficiency was unexpectedly low. This may have been the result of transfecting an 
insufficient quantity of siRNAs or using siRNAs that bind weakly to the target mRNA. As 
such, the silencing procedure was carried out once more, using new siRNAs for eIF3h 
(siRNA eIF3h2, table 2) and eIF3f (siRNA eIF3f2, table 2) and with an additional 
transfection, 24h after the initial treatment (fig. 14). This resulted in the depletion of 
eIF3f protein, but eIF3h knockdown failed, indicating that the siRNA eIF3h2 (fig. 14A) is 
even more ineffective than siRNA eIF3h1 (fig. 10A versus fig.14A). Interestingly, eIF3c 
silence using the same siRNA, but with an additional transfection step, had similar 
results. This is easily explained by the fact that eIF3c protein has a half-life of 15.1h122 
and therefore more time is needed between transfection and lysis to see any 
difference. Additionally, in IP of mRNPs from HeLa cell lysates treated with eIF3h 
siRNAs, a decrease of ≥ 50% of the eIF3h mRNA level was observed (fig. 13), while the 
protein level remained unchanged (fig. 12). This could suggest that eIF3h has a high 
stability and there was not enough time to decrease the protein population, between 
the transfection and lysis.   
Despite the silence procedure not being satisfactory in both IPs, there are still 
some results that can be pointed out. Remarkably, in IP samples of HeLa cells treated 
with eIF3f specific siRNAs (fig. 11), CBP80, eIF4G and PABPC1 co-precipitated with 
eIF3h and were detected in a RNA independent manner. This supports the idea that 
CBP80 bound mRNAs also acquire an mRNP circularization conformation analogous to 
the well-characterized eIF4E-eIF4G-PABPC1 interaction that brings the 5′ and 3′ ends of 
mRNAs close together39. Additionally, this data is in accordance with the results by 
Lejeune and Chiu27,123 that suggests that eIF4G and PABPC1 have a function in the 
pioneer initiation complex rather than being merely a presence during remodeling to 
the steady-state complex, indicating that there is a degree of mechanistic conservation 
between the pioneer round of translation and steady-state translation. Our findings 
also show that treatment with eIF3f siRNAs leads to lower levels of PABPC1 and eIF4G 
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(fig. 11). This could support a model where the eIF3f subunit is involved in bringing 
PABPC1 (through eIF4G) into the vicinity of the AUG. However, the difference is small 
in nature (and arguable), as a result of the low silencing efficiency. If a better efficiency 
could be obtained, perhaps a greater impact on PABPC1 and eIF4G protein levels 
would be observed in IP samples treated with eIF3f siRNAs.  
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6. Conclusion and future directions 
 
NMD is increasingly appreciated as one of the central mechanisms of mRNA 
surveillance, with an important role both in the physiological control of gene 
expression and in modulating diseases associated with PTCs. The detailed study of this 
mechanism will certainly aid in the development of new tools to be implemented in 
therapies for PTC related pathologies. But, despite having been thoroughly scrutinized 
for several years, the molecular basis underlying the NMD surveillance pathway has 
still not been fully elucidated.  
PABPC1 has shown a major role in protecting AUG proximal PTCs from NMD. In 
this thesis we tried to construct the tools necessary to investigate the interaction of 
PABPC1 with the ribosome, during initiation and the first steps of elongation. Once 
completed, the pTre_βWT_3xMS2bs(45nt_CD39) could be subjected to direct 
mutagenesis to create β-globin variants with nonsense mutations in codons 15, 23, 26 
and 39. Immunoprecipitation assays of the resultant mRNPs in the presence of RNAse 
H and specific ssDNA probes, to specifically digest the mRNA in the 5’ UTR and 
downstream of the MS2bs, would permit to capture the mRNA fragment with a 
ribosome near the AUG or premature stop codon. The presence of PABPC1, ribosomal 
complex proteins and NMD factors could then be assessed by Western blot. Treatment 
with cycloheximide would facilitate the capture of the mRNPs near the AUG. 
Furthermore, the role of the eIF3f and eIF3h subunits in pulling the 
PABPC1/eIF4G complex with the 43S subunit during ribosomal scanning and 
translation initiation was also explored. The data presented here point to a model 
where eIF3f is indeed involved in this interaction, but both IP and silence procedures 
should be optimized before solid results can be obtained. 
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